Answers are grounded in this paper and cite their sources.
Im We describe here a single-center case series of 27 IC COVID-19 inpatients (mostly with haematological disorders) treated with a combined therapy based on tixagevimab/cilgavimab (T/C) plus small-molecule antivirals (AV), between April 1 2022 and November 30 2022.
No takes yet. Share an insight, caveat, or question.
Vita et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: